医学
放射治疗
剂量分馏
阶段(地层学)
肿瘤科
肺癌
化疗
预防性头颅照射
核医学
放射科
内科学
古生物学
生物
心肌梗塞
传统PCI
作者
Jiayi Yu,Leilei Jiang,Lina Zhao,Jing Wang,Xiaomin Wang,Jing Wang,Minglei Zhuo,Hanxiao Chen,Wei Huang,Zhengfei Zhu,Min Zhang,Yipeng Song,Quanfu Li,Zhanshu Ma,Qifeng Wang,Yanli Qu,Rong Yu,Hui-Ming Yu,Jun Zhao,Anhui Shi
标识
DOI:10.1016/s2213-2600(24)00189-9
摘要
For the past 20 years, twice-daily thoracic radiotherapy with concurrent chemotherapy has been the treatment of choice for limited-stage small-cell lung cancer (LS-SCLC), which has a poor prognosis. We aimed to assess the efficacy and safety of high-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy in 30 fractions) versus standard-dose radiotherapy (45 Gy in 30 fractions) as a first-line treatment for LS-SCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI